Last updated: April 2020
The NHS England tariff-excluded drugs list describes those specialised medicines which are not reimbursed through national prices and are commissioned directly through NHS England. The following tables enable you to search by:
- drug names and indications
- the relevant technology appraisal or commissioning policy
- where to look for the criteria for starting and stopping a medication
- monitoring and audit requirements
- where a drug is only appropriate for a specialist centre
- whether a drug is suitable for shared care (e.g. between specialist and secondary care, or with primary care).
- where a drug is marked as ‘Specialist centre only’, this includes outreach when delivered as part of a provider network
- where a drug is marked as ‘Suitable for shared care with primary care’, this is only if supported by the local prescribing committee.
A list of footnotes can be found at the bottom of this page.
Medicines not reimbursed through national prices and directly commissioned by NHS England
|wdt_ID||Drug name||Indication||TA/Policy||Starting criteria||Stopping criteria||Monitoring/audit requirements||Specialist centre only?||Suitable for shared care between specialist and secondary care?||Suitable for shared care with primary care?|
|1||ABACAVIR||HIV IN COMBINATION WITH OTHER ANTI- RETROVIRAL DRUGS||AGREED REGIONALGUIDELINES||BHIVA GUIDELINES (8)||BHIVA GUIDELINES (8)||HARS DATASET||✔|
|2||ABACAVIR + LAMIVUDINE + DOLUTEGRAVIR (TRIUMEQ®)||HIV IN COMBINATION WITH OTHER ANTI- RETROVIRAL DRUGS||NHS ENGLAND CLINICAL COMMISSIONING POLICY: B06/P/b/AGREED REGIONAL GUIDELINES||BHIVA GUIDELINES (8)||BHIVA GUIDELINES (8)||HARS DATASET||✔|
|3||ABACAVIR + LAMIVUDINE||HIV IN COMBINATION WITH OTHER ANTI- RETROVIRAL DRUGS||AGREED REGIONALGUIDELINES||BHIVA GUIDELINES (8)||BHIVA GUIDELINES (8)||HARS DATASET||✔|
|4||ABALOPARATIDE||MALE AND JUVENILE OSTEOPOROSIS||NOT ROUTINELY COMMISSIONED||AS PER IFR APPROVAL||AS PER IFR APPROVAL||AS PER IFR APPROVAL||✔|
|5||ABATACEPT||JUVENILE ARTHRITIS-PAEDIATRIC||NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/d; TA 373||NHS ENGLAND POLICY||NHS ENGLAND POLICY||NHS ENGLAND POLICY||✔|
|6||ABIRATERONE||CANCER||TA259, 387 (SEE ALSO SSC1438) ONLY IN ENZALUTAMIDE NAÏVE PATIENTS||NICE/NHS ENGLAND POLICY||NICE||SACT||✔|
|7||ADALIMUMAB||JUVENILE ARTHRITIS-PAEDIATRIC||NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/d; TA 373||NHS ENGLAND POLICY||NHS ENGLAND POLICY||NHS ENGLAND POLICY||✔|
|8||ADALIMUMAB||UVEITIS - ADULTS||TA460||NICE||NICE||NICE AUDIT||✔|
|9||ADALIMUMAB||BEHCETS SYNDROME||HIGHLY SPECIALISED CRITERIA ONLY||HIGHLY SPECIALISED CRITERIA ONLY||HIGHLY SPECIALISED CRITERIA ONLY||HIGHLY SPECIALISED CRITERIA||✔|
|10||ADALIMUMAB||HIDRADENITIS SUPPURATIVA||NICE TA 392||NICE||NICE||NICE AUDIT||✔|
|Drug name||Indication||TA/Policy||Starting criteria||Stopping criteria||Monitoring/audit requirements||Specialist centre only?||Suitable for shared care between specialist and secondary care?||Suitable for shared care with primary care?|
Other drugs not listed under payment by results (PbR) exclusions
|wdt_ID||Drug name||Indication||TA/Policy||Starting criteria||Stopping criteria||Monitoring/audit reuqirements||Specialist centre only||Suitable for shared care between specialist and secondary care||Suitable for shared care with primary care|
|2||3,4 DIAMINOPYRIDINE||LAMBERT EATON MYASTHENIC SYNDROME||AGREED TRUST GUIDELINES||TRUST GUIDELINES||TRUST GUIDELINES||✔|
|3||ABEMACICLIB||CANCER||TA563 CDF TA579||NICE CDF||NICE CDF||SACT||✔|
|4||ALBUMIN BOUND PACLITAXEL||CANCER||TA 476||NICE||NICE||SACT||✔|
|6||ARSENIC TRIOXIDE||CANCER||TA 526 NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY STATEMENT 170072P||NICE||NICE||SACT||✔|
|7||ATEZOLIZUMAB||CANCER||TA520, TA525, TA584 CDF (TA 492)||NICE CDF||NICE CDF||SACT||✔|
|8||AUTOLOGOUS CHONDROCYTE IMPLANTATION||ARTICULAR CARTILAGE DEFECT||TA 477 & TA 508||NICE||NICE||NICE AUDIT||✔|
|9||AVELUMAB||CANCER||TA 517 CDF||NICE CDF||NICE CDF||SACT||✔|
|10||AXICABTAGENE CILOLEUCEL||CANCER||TA 559||CDF||CDF||SACT||✔|
|11||AZATHIOPRINE||TRANSPLANT IMMUNOSUPPRESSION ONLY||NEW PATIENTS ONLY UNTIL FORMAL REPATRIATION AGREED||TRUST GUIDELINES||TRUST GUIDELINES||✔*||✔*|
|Drug name||Indication||TA/Policy||Starting criteria||Stopping criteria||Monitoring/audit reuqirements||Specialist centre only||Suitable for shared care between specialist and secondary care||Suitable for shared care with primary care|
* Drug is being repatriated from primary to secondary care therefore supply route may vary at present
** Routinely commissioned in combination when dual therapy required
*** Only when prescribed in an adult specialist centre
**** Only where it is a recognised multiple sclerosis (MS) centre with specialist nurse support
- Where the funded indication is for paediatric use the CCG will become the responsible commissioner when the patient is transferred to the adult service
- CCGs are the responsible commissioner for rituximab in adult non-cancerous haematological conditions (e.g. immune thrombocytopaenic purpura) and non-specialist auto-inflammatory conditions (e.g. rheumatoid arthritis)
- Eltrombopag and romiplostim are the responsibility of CCGs regardless of the cause of the thrombocytopenia in adults (paediatrics are NHS England responsibility)
- It is a mandated requirement that all use of chemotherapy is recorded in the Systemic Anti-Cancer Therapy (SACT) database including those treatments funded through the Cancer Drugs Fund
- Use in vascular disease is commissioned by NHS England within specialist centres—CCGs are responsible for all other indications
- NHS England is the responsible commissioner when somatropin analogues (growth hormone) are prescribed in specialist centres for indications falling outside NICE guidance
- NHS England commissions anti-retrovirals (ARVs) as per published policies, for the treatment of people with diagnosed HIV infection and for those thought to be HIV positive (post-exposure prophylaxis). NHS England does not routinely commission pre-exposure prophylaxis and this is only available to those enrolled in clinical studies or other NHS England agreed schemes
- Drugs approved by NICE for adult conditions will be commissioned in children at specialised paediatric centres if the patient meets the NICE criteria and there is evidence to suggest that the drug is safe and clinically appropriate to use in children as per the NHS England medicines for children policy and a BlueTeq form is available. This includes drugs normally commissioned by CCGs in adults e.g. adalimumab, etanercept, infliximab etc. Please note that medicines funded under the NHS England medicines for children policy may have additional criteria with respect to access.
Products that are currently available via the Early Access to Medicines Scheme are not covered by this list but all require registration via the Blueteq system.
Contains public sector information licensed under the Open Government License v3.0.
The original version of this table can be found on the NHS England website.